These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 5309489)

  • 1. Future influenza vaccines and the use of genetic recombinants.
    Kilbourne ED
    Bull World Health Organ; 1969; 41(3):643-5. PubMed ID: 5309489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the haemagglutinin production of influenza A2 Hong Kong variant and recombinant strains.
    Tauraso NM; O'Brien TC
    Bull World Health Organ; 1970; 43(2):275-9. PubMed ID: 5312524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic properties resulting from directed gene segment reassortment between wild-type A/Sydney/5/97 influenza virus and the live attenuated vaccine strain.
    Parks CL; Latham T; Cahill A; O'neill RE; Passarotti CJ; Buonagurio DA; Bechert TM; D'Arco GA; Neumann G; Destefano J; Arendt HE; Obregon J; Shutyak L; Hamm S; Sidhu MS; Zamb TJ; Udem SA
    Virology; 2007 Oct; 367(2):275-87. PubMed ID: 17599381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characteristics and biological properties (genetic markers) of candidate strains for preparation of live influenza virus vaccines.
    Ghendon YZ
    Bull World Health Organ; 1984; 62(3):493-9. PubMed ID: 6331910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant influenza-virus vaccines: I. Rapid derivation and preliminary characterization of high-yielding recombinants of influenza virus.
    Higashihara M; Igarashi Y; Nakagawa S; Saito Y
    Kitasato Arch Exp Med; 1976 Jun; 49(1-2):1-26. PubMed ID: 1025339
    [No Abstract]   [Full Text] [Related]  

  • 6. Laboratory and clinical evaluation of new live influenza virus vaccines. Need for minimum requirements.
    Huygelen C
    Dev Biol Stand; 1977 Jun 1-3; 39():155-60. PubMed ID: 342307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-yield reassortant influenza vaccine production virus has a mutation at an HLA-A 2.1-restricted CD8+ CTL epitope on the NS1 protein.
    Terajima M; Jameson J; Norman JE; Cruz J; Ennis FA
    Virology; 1999 Jun; 259(1):135-40. PubMed ID: 10364497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
    Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
    Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditions for production of thermosensitive attenuated influenza virus recombinants.
    Polezhaev FI; Garmashova LM; Polyakov YM; Golubev DB; Aleksandrova GI
    Acta Virol; 1978 Jul; 22(4):263-9. PubMed ID: 29464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Genetic techniques for the production of influenza vaccines (author's transl)].
    Teti G
    Ann Sclavo; 1980; 22(1):34-9. PubMed ID: 7018413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [On the antigenicity of influenza virus aluminum oxide adjuvant vaccine "Alorbat" in man (author's transl)].
    Desselberger U; Pressler K; Erdmann G
    Zentralbl Bakteriol Orig A; 1975 Jul; 232(2-3):160-77. PubMed ID: 1179878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies with live attenuated influenza vaccines.
    Douglas RG; Betts RF
    Am J Clin Pathol; 1978 Jul; 70(1 Suppl):153-8. PubMed ID: 685888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory and clinical characteristics of attenuated strains of influenza virus.
    Maassab HF; Francis T; Davenport FM; Hennessy AV; Minuse E; Anderson G
    Bull World Health Organ; 1969; 41(3):589-94. PubMed ID: 5309481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.
    de Wit E; Munster VJ; Spronken MI; Bestebroer TM; Baas C; Beyer WE; Rimmelzwaan GF; Osterhaus AD; Fouchier RA
    J Virol; 2005 Oct; 79(19):12401-7. PubMed ID: 16160167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on genetic recombinants of influenza virus: fundamental studies on recombinant influenza-virus vaccines.
    Higashihara M
    Kitasato Arch Exp Med; 1975 Dec; 48(4):183-8. PubMed ID: 1234926
    [No Abstract]   [Full Text] [Related]  

  • 16. Attenuated influenza B virus recombinants obtained by crossing of B/England/2608/76 virus with a cold-adapted B/Leningrad/14/17/55 strain.
    Medvedeva TE; Gordon MA; Ghendon YZ; Klimov AI; Alexandrova GI
    Acta Virol; 1983 Jul; 27(4):311-7. PubMed ID: 6195900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experiments in the preparation of live influenza B vaccines.
    Beare AS; Sherwood JE; Callow KA; Craig JW
    Dev Biol Stand; 1977 Jun 1-3; 39():85-9. PubMed ID: 604138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live viruses for immunization against influenza.
    Beare AS
    Prog Med Virol; 1975; 20():49-83. PubMed ID: 1105681
    [No Abstract]   [Full Text] [Related]  

  • 19. Recombinants of influenza virus type B as potential live vaccine candidates: RNA characterization and evaluation in man.
    Lobmann M; Delem A; Jovanovic D; Peetermans J
    J Hyg (Lond); 1981 Aug; 87(1):43-52. PubMed ID: 7019320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and characterization of live recombinant influenza vaccine.
    Stealey VM; McCahon D; Freestone DS
    Dev Biol Stand; 1976; 33():191-6. PubMed ID: 955267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.